In reference to the above-mentioned article in Seminars in Thrombosis and Hemostasis,
Volume 34, Number 1, pages 58–73, a nonreferenced statement regarding the closure
of a large clinical trial with prasugrel due to bleeding was made due to an inadvertent
misinterpretation. Upon review of the published data on the clinical trials on prasugrel
and the ongoing trials, the authors did not find any information on the closure of
either a large or small trial on this drug. The authors acknowledge the readjustment
of the recruitment schedule of two smaller trials, which were temporarily suspended
last year, and that have since either completed enrollment or are still enrolling
participants. The authors regretfully acknowledge the statement made in the aforementioned
article, reaffirm that to their knowledge that no large clinical trials with prasugrel
have been closed due to bleeding, and will accordingly update this information in
their records and future publications.
